Abstract

Leveraging Novel Technologies for Human iPSC-based Screening

Xianmin Zeng, Associate Professor, Buck Institute for Research on Aging

In collaboration with the NIH, Buck Institute and Sigma-Aldrich, XCell has developed a large panel of genetically engineered human iPSC lines including 1) control lines, 2) lines from patients with mono allelic disease, 3) knock-in reporter lines, 4) isogenic controls of single and double knock-outs. Equally importantly, we are able to produce large numbers of differentiated cells including neural stem cells, neurons and astrocytes in an assay ready format from these engineered iPSC lines, and run demonstration screens for neuroprotective and neurotoxic effects.